Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice
Authors:
- 27 December 2012
- journal article
- research article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 28 (5) , 855-860
Abstract
Background and Aim: Treatment end‐point of therapy for patients with hepatitis B e antigen (HBeAg)‐positive chronic hepatitis B (CHB) includes HBeAg seroconversion, which ranges from 15% to 22% after 1 year of oral nucleos(t)ides according to clinical trials. Our goal was to determine the incidence and predictors of HBeAg seroconversion in such patients in routine clinical practice because they may differ than reported rates.Methods: We conducted a retrospective cohort study of 333 consecutive treatment‐naïve HBeAg‐positive patients who were treated for CHB between 1/2000 and 6/2010 at three gastroenterology and liver clinics in the USA. Primary study end‐point was HBeAg seroconversion—loss of HBeAg and antibody to HBeAg (anti‐HBe) development.Results: The majority of patients were Asian (96%). Median treatment duration prior to HBeAg seroconversion was 50 (range 26–52) weeks. Of the 333 study patients, 25% received lamivudine, 16% adefovir, 51% entecavir, and 8% tenofovir. HBeAg seroconversion at month 12 was 8.2%. On multivariate analysis inclusive of age, gender, and antiviral agents, independent predictors for HBeAg seroconversion at month 12 were hepatitis B virus DNA < 7.5 log10 IU/mL (hazard ratio [HR] = 2.59 [1.04–6.44]), P = 0.041) and alanine transaminase (ALT) > 1.5 × upper normal limit (HR = 2.86 [1.05–7.81], P = 0.040), but not the choice of nucleos(t)ides.Conclusions: The HBeAg seroconversion rate seen in clinical settings for oral nucleos(t)ides appears much lower than those reported in pivotal trials, especially in patients with lower ALT and higher HBV DNA levels. HBeAg‐positive patients should be counseled about the high possibility of the long treatment duration required to achieve recommended treatment end‐points.Keywords
This publication has 36 references indexed in Scilit:
- Hepatitis B e Antigen Seroconversion: A Critical Event in Chronic Hepatitis B Virus InfectionDigestive Diseases and Sciences, 2010
- Chronic hepatitis B: Update 2009 #Hepatology, 2009
- HBeAg seroconversion as an important end point in the treatment of chronic hepatitis BHepatology International, 2009
- A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2008 UpdateClinical Gastroenterology and Hepatology, 2008
- Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 updateHepatology International, 2008
- Chronic hepatitis BHepatology, 2007
- Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA LevelJAMA, 2006
- Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver DiseaseNew England Journal of Medicine, 2004
- Hepatitis B Virus InfectionNew England Journal of Medicine, 1997
- Hepatitis B virus.The major etiology of hepatocellular carcinomaCancer, 1988